美国代谢与减重手术学会2016年最新立场声明解读

Interpretation of the updated position statements on bariatric surgery and implantable devices from American Society for Metabolic and Bariatric Surgery in 2016

2016年4月,美国代谢与减重手术学会就代谢与减重手术的长期生存获益、胃内球囊和迷走神经阻断治疗病态肥胖症等阐述最新原则立场。该系列声明认为,越来越多的临床证据表明减重和代谢手术是病态肥胖症最有效的治疗手段,并着重强调了长期的减重和生存获益是手术区别于非手术治疗手段的主要优势;根据美国胃肠道和内镜外科医师协会提供的资料,胃内球囊可以有效、安全地治疗肥胖症;基于目前的短期证据,作为一种新型减重装置,迷走神经阻断装置适用于BMI为35~45的病人,但其减重效果的长期有效性和病人耐受性仍有待继续观察。

The American Society for Metabolic and Bariatric Surgery （ASMBS） has issued a series of position statements in April 2016 in response to numerous inquiries made to the Society by patients, physicians, hospitals, the media, and others regarding the metabolic and bariatric surgery and two kinds of implantable devices. Data suggest that metabolic and bariatric surgery may improve survival and longevity, relative to the nonsurgical usual care treatment of individuals with class Ⅱ and Ⅲ obesity. The Society of American Gastrointestinal and Endoscopic Surgeons （SAGES） provided an overview of the available evidence regarding the clinical utility, efficacy, and safety of endoscopically placed intragastric balloon for obesity and related diseases. The technology of intragastric balloons and its application in the treatment of obesity were approved by ASMBS and SAGES. A new device for weight loss called vagal blocking therapy for obesity （VBLOC） was approved for patients with a body mass index （BMI） 35 to 45 kg/m2. Based on current evidence available, the long-term efficacy and adverse events of this new technology should be further established.